Health and Healthcare
Johnson & Johnson Pharmaceutical, Domestic Sales Fuel Growth
Published:
Last Updated:
Johnson & Johnson (NYSE: JNJ) reported its fiscal third-quarter financial results before the markets opened on Tuesday. The company said that it had $1.90 in earnings per share (EPS) and $19.7 billion in revenue, which compares with consensus estimates from Thomson Reuters of $1.80 in EPS and revenue of $19.28 billion. In the same period of last year, it posted EPS of $1.68 and $17.82 billion in revenue.
Domestic sales increased 9.7%. International sales increased 10.9%, reflecting operational growth of 9.3% and a positive currency impact of 1.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide, domestic and international sales each increased 3.8%.
In terms of its segments, the company reported:
- Worldwide Consumer revenues of $3.4 billion increased 2.9% over the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%.
- Worldwide Pharmaceutical revenues of $9.7 billion represented an increase of 15.4% from the prior year, with an operational increase of 14.6% and a positive impact from currency of 0.8%.
- Worldwide Medical Devices revenues of $6.6 billion increased by 7.1% compared to last year, consisting of an operational increase of 6.6% and a positive currency impact of 0.5%.
As for the full year outlook, Johnson & Johnson increased both its EPS forecast to $7.25 to $7.30 and sales guidance to $76.1 billion to $76.5 billion. The consensus estimates call for $7.18 in EPS and $75.83 billion in revenue.
Alex Gorsky, board chair and CEO, commented:
Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth. Our dedicated colleagues continue to focus on advancing our pipelines to bring innovative solutions to patients and consumers around the globe.
Shares of Johnson & Johnson traded up 1% early Tuesday at $137.52, with a consensus analyst price target of $138.80 and a 52-week trading range of $109.32 to $137.52.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
